Tag: GlobeNewswire

CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1

Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors

Access the Ernexa CEO Corner here 

CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today released a new installment of its CEO Corner series featuring President and Chief Executive Officer Sanjeev Luther. The discussion highlights the recent appointment of Robert J. Spiegel, M.D., FACP, to the Company’s Board of Directors and how his deep oncology, clinical development and regulatory experience strengthens Ernexa as it sharpens its oncology focus and advances lead program ERNA-101 toward the clinic.

Dr. Spiegel brings decades of experience spanning oncology, clinical development, regulatory strategy and pharmaceutical leadership, including more than 25 years at Schering-Plough Research Institute, where he ultimately served as Chief Medical Officer.

“We believe Ernexa is entering one of the most important periods in our evolution, and Dr. Spiegels’s addition to the Board comes at a highly relevant time,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. “His experience aligns directly with where we are headed as we move ERNA-101 toward the clinic. With meaningful development milestones ahead and a broader opportunity across difficult-to-treat solid tumors, we believe we are building a strong foundation for Ernexa’s next stage of growth.”

ERNA-101 is initially being developed for platinum-resistant ovarian cancer and is designed to leverage the tumor-homing properties of iMSCs to deliver immune-enhancing cytokines directly into the tumor microenvironment. The program is also designed to address immunologically “cold” tumors, supporting potential expansion into additional difficult-to-treat solid tumors.

Ernexa has completed IND-enabling preclinical studies for ERNA-101, clinical-grade manufacturing is underway, and the Company is targeting an IND submission in the fourth quarter of 2026, followed by initiation of a first-in-human study in the first quarter of 2027.

The CEO Corner also highlights encouraging preclinical findings supporting ERNA-101. In an ovarian cancer model, ERNA-101 in combination with anti-PD-1 demonstrated complete tumor clearance and 100% survival, further supporting the scientific rationale for the program as Ernexa prepares for clinical development.

Dr. Spiegel’s experience across first-in-human, proof-of-concept and registration-stage development is particularly relevant as Ernexa approaches clinical evaluation.

“ERNA-101 represents a compelling approach to addressing some of the persistent challenges in ovarian cancer,” said Dr. Spiegel. “I am encouraged by the progress Ernexa has made as ERNA-101 approaches clinical development and look forward to contributing my experience as the Company advances this program and its broader oncology strategy.” His appointment further strengthens Ernexa’s oncology, regulatory and clinical development expertise as the Company approaches key milestones.”

Beyond ERNA-101, Ernexa is advancing next-generation oncology assets, including ERNA-102 and ERNA-103, as it works to build a differentiated portfolio of engineered iMSC therapies across solid tumors.

As Ernexa advances its oncology strategy, hope and accessibility remain central to the Company’s vision. Its allogeneic, off-the-shelf approach is designed with scalability in mind, with the goal of expanding accessibility while bringing meaningful new options and renewed hope to patients facing difficult-to-treat cancers.

The CEO Corner concludes with Mr. Luther outlining Ernexa’s priorities: advancing ERNA-101 into the clinic, generating human data and building a differentiated oncology company around the broader potential of its synthetic iMSC platform.

The Ernexa CEO Corner is now accessible on the Company’s website and social media channels. Access it here.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: the Company’s ability to advance ERNA-101 toward and submit an IND application to the FDA, including the planned submission in Q4 2026; the timing, design and outcomes of the planned first-in-human clinical study of ERNA-101 in platinum-resistant ovarian cancer, including the expected availability of clinical data in Q4 2027; the Company’s ability to transition from a preclinical-stage company to a clinical-stage company; expectations regarding the versatility and therapeutic potential of the Company’s synthetic iMSC platform, including its ability to be engineered for distinct therapeutic purposes across oncology and other disease areas; the Company’s plans to broaden its oncology pipeline by evaluating additional high-need cancer indications and advancing next-generation iMSC candidates; the Company’s ability to identify, develop and advance additional product candidates; the Company’s capital allocation strategy, including the decision to pause additional preclinical development expenditures on ERNA-201 and concentrate near-term resources on ERNA-101 and oncology pipeline expansion; the potential for ERNA-201 to be advanced in the future; the Company’s ability to enter into strategic collaborations or partnerships; the sufficiency of the Company’s capital resources to fund planned operations and achieve anticipated milestones; the Company’s ability to obtain and maintain regulatory approvals for its product candidates; the Company’s ability to attract and retain qualified personnel; the Company’s ability to protect its intellectual property and proprietary technology; competition from other companies developing therapies for the same or similar indications; and general market, political and economic conditions. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date here of, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

Company clarifies its prior 10% investment and has filed an 8-K covering the proposed transaction

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — Creatd, Inc. (OTCQB: CRTD) today announced that it has entered into a binding letter of intent to acquire the remaining 90% of C2 Capital Group, operator of C2 Live, a live-streaming platform. The proposed transaction follows Creatd’s previously announced 10% investment in C2, which was disclosed in the Company’s Form 8-K filed with the Securities and Exchange Commission.

The LOI targets a closing on Oct. 31, 2026. The Company has filed a Form 8-K describing the LOI and the proposed transaction. The reported transaction terms include approximately $2.5 million of cash held by C2 at closing and a $500,000 mutual breakup fee. These figures and the closing target remain subject to final documentation, approvals and completion of diligence.

The reported consideration for the remaining 90% has been described as approximately 20% common and 80% non-voting preferred. Options are not included in this announcement. The consideration structure, including the common and preferred allocation, remains subject to final documentation and confirmation.

The transaction remains subject to board approval, legal review, completion of the C2 audit process and other closing conditions. There can be no assurance that the transaction will be completed on the terms described or at all.

“This is the next step in a process we are running deliberately. The 10% investment gave us the opportunity to work with C2 Live and evaluate the business directly. We are now working toward the remaining 90%, but the closing target does not replace the diligence, documentation and approvals required to complete the transaction,” said Jeremy Frommer, Chairman and Chief Executive Officer of Creatd, Inc.

About Creatd, Inc.
Creatd, Inc. (OTCQB: CRTD) is a company focused on technology-enabled businesses, digital media properties, and intellectual property assets. Through its operating subsidiaries and strategic investments, the Company develops and supports opportunities for creators, entrepreneurs, and emerging growth initiatives.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations, estimates, and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Creatd undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Contact:
ir@creatd.com

SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — BioCardia^®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter (“Helix”) for therapeutic and diagnostic agent delivery to the heart.

In May 2026, the Company and FDA met and reviewed our initial DeNovo pre-submission. FDA agreed that there are two pathways for Helix marketing clearance and raised no concerns regarding the Helix safety data, device performance, or compatibility with general classes of agents. In August 2026, the FDA confirmed and accepted the meeting minutes as summarized by BioCardia. The revised De Novo pre-submission for the Helix catheter incorporates the advice from FDA CDRH detailed in the minutes.

Should FDA enable Helix to be the first device of its kind cleared for market release by FDA, the extensive clinical data and safety profile from 15 clinical trials including nearly 500 patients presents opportunities for FDA to ensure that follow-on catheters demonstrate non-inferiority to the Helix catheter safety profile and clinical experience prior to their marketing clearance.

The FDA targets providing an initial acceptance/refusal review within 15 calendar days and aims to issue written feedback or hold a meeting within 70 calendar days.

An independent FDA clearance of Helix has the potential to expand BioCardia’s opportunities to partner with developers of investigational cell, gene and protein therapeutics requiring targeted delivery to the heart.

About BioCardia

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP™ autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph^® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information, visit www.biocardia.com.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to the timing and potential outcome of BioCardia’s regulatory submissions for the Helix catheter.

These forward-looking statements are made as of the date of this press release. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release.

Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials and regulatory programs. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact:
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120

Customer service improvements come without adding headcount or increasing staffing costs

SCHAUMBURG, IL, Oct. 01, 2026 (GLOBE NEWSWIRE) — Giftify, Inc. (NASDAQ: GIFT) (the “Company”), the owner and operator of CardCash.com, Restaurant.com, and Takeout7.com, and a leader in the incentives and rewards industry, today announced that CardCash has cut average customer service response times by more than 90% across a support operation that handles approximately 5,000 tickets per month, without increasing overall staffing costs, through a series of AI-assisted customer service and operational improvements.

A key part of the initiative is a dynamic AI-powered customer service system that helps gather the information an agent needs before an inquiry reaches the support team. The system reviews each customer request, identifies information that may be missing and prompts the customer for relevant details. It can also retrieve available account or support information and help route the inquiry to the appropriate team.

This reduces unnecessary back-and-forth between customers and agents and allows the support team to address issues more quickly.

The improvements were led by Abe Nojowitz, Vice President of Operations at CardCash, and extend beyond AI. CardCash reallocated its existing customer service staffing across the week to match customer demand, preventing backlogs and evening out agent workload without adding headcount.

CardCash also carved out dedicated time for agents to follow up on unresolved inquiries, so open issues keep moving toward resolution instead of being overtaken by new requests, and completed a comprehensive review of its customer service macros, responses and templates for accuracy, consistency and efficiency.

“Together, AI and the operational changes we made have cut our response times by more than 90% without increasing staffing costs,” said Abe Nojowitz . “We looked at the entire customer service process and focused on removing the things that slow agents down. AI helps us collect better information before an inquiry reaches the team, while the operational changes make sure the right resources are available when customers need them.”

“AI is becoming part of how we run this business, and this is one more example of that focus translating into measurable results,” said Ketan Thakker, President and Chief Executive Officer of Giftify, Inc. “We continue to look for practical ways to apply AI and other technology across CardCash, and we’ll keep investing in the tools that make our operations more efficient as we build long-term value for our shareholders.”

CardCash plans to continue investing in practical applications of AI and operational improvements that help its teams work more efficiently while delivering a better customer experience.

About Giftify, Inc.

Giftify, Inc. (NASDAQ: GIFT) is a pioneer in the incentive and rewards industry with a focus on retail, dining, and entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com and Restaurant.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales from over 1,100 retailers. Restaurant.com is the nation’s largest restaurant-focused digital deals brand, connecting digital consumers, businesses, and communities by offering thousands of dining, retail, and entertainment deal options nationwide at over 184,000 restaurants and retailers. For more information, visit www.giftifyinc.com, www.cardcash.com, and www.restaurant.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding Giftify’s future financial and operational performance, business strategy, and market position. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to: changes in consumer spending patterns; competition in the gift card and restaurant deals markets; the Company’s ability to maintain and expand relationships with merchants and corporate clients; the Company’s ability to achieve and maintain profitability; the Company’s liquidity and ability to raise additional capital; general economic conditions; and other risks detailed in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company has identified substantial doubt about its ability to continue as a going concern, as disclosed in the accompanying Form 10-Q; see the Form 10-Q for further detail. The forward-looking statements in this press release are made as of the date hereof, and Giftify undertakes no obligation to update these statements or to explain the reasons why actual results may differ.

Investor Contact: Giftify, Inc. | IR@giftifyinc.com

PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month

Validation confirms that the application is complete and EMA initiates formal review of D-PLEX₁₀₀

D-PLEX₁₀₀ NDA concurrently under FDA Priority Review with November 28, 2026 PDUFA goal date

PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that the European Medicines Agency (“EMA”) has validated the Company’s recently submitted Marketing Authorization Application (“MAA”) for D-PLEX₁₀₀, its lead product candidate for the prevention of post abdominal surgery incisional infections. The application will now enter formal review by the EMA’s Committee for Medicinal Products for Human Use.

The MAA was submitted to the EMA on September 14, 2026 under the Centralized Procedure on the basis of therapeutic innovation.  Validation confirms that the application is complete and marks the initiation of a formal regulatory review process. The submission follows productive meetings the Company held with the EMA Rapporteur and Co-Rapporteur during the second quarter of 2026 regarding the planned application. If approved, D-PLEX₁₀₀ would receive a single marketing authorization valid throughout the European Union member states.

The application is supported by PolyPid’s clinical development program for D-PLEX₁₀₀, including the positive pivotal Phase 3 SHIELD II trial, which met its primary endpoint and all key secondary endpoints and demonstrated a 60% relative risk reduction in surgical site infections (“SSIs”) compared with standard of care (p=0.0013).

“Validation of the MAA for D-PLEX₁₀₀ marks another important step toward potential commercialization in major global markets,” said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. “With our New Drug Application (“NDA”) already under Priority Review in the United States and our European application now submitted and validated, we continue to advance D-PLEX₁₀₀ toward potential regulatory approval on both sides of the Atlantic. Now that D-PLEX₁₀₀ is at an advanced stage of regulatory development, we see a meaningful opportunity to maximize the value of this asset in the significant European SSI market and are excited by the strategic possibilities ahead.”

The U.S. Food and Drug Administration (“FDA”) has accepted PolyPid’s NDA for D-PLEX₁₀₀ and granted Priority Review, with a Prescription Drug User Fee Act (“PDUFA”) goal date of November 28, 2026. PolyPid retains commercial rights to D-PLEX₁₀₀ outside the U.S and Canada, where the Company has partnered with Azurity Pharmaceuticals.

About D-PLEX₁₀₀
D-PLEX₁₀₀, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site with the goal of preventing abdominal surgical site infections (“SSIs”). Following the administration of D-PLEX₁₀₀ into the surgical site, PolyPid’s delivery technology, Kynatrix, is designed to pair with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. In the Phase 3 SHIELD II trial, D-PLEX₁₀₀ recently demonstrated positive results in achieving its primary end point and a 60% (p=0.0013) relative risk reduction at the secondary end point in SSI incidence following abdominal colorectal surgery with large incisions. D-PLEX₁₀₀ received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated timing and requirements of the EMA review process, the potential approval of D-PLEX₁₀₀ through the EMA’s Centralized Procedure and the potential commercialization of D-PLEX₁₀₀ across European Union member states, meaningful opportunity to maximize the value of  D-PLEX₁₀₀ in the significant European SSI market, the strategic possibilities ahead, the FDA’s Priority Review of the D-PLEX₁₀₀ NDA and the November 28, 2026 PDUFA goal date and the potential FDA approval of D-PLEX₁₀₀. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities

The acquisition adds advanced yeast-breeding expertise with a proven track record in bioethanol and broader potential across industries.

COPENHAGEN, Denmark, October 1 – Novonesis today announced the completion of its acquisition of MicroBioGen, an Australian biotechnology company with leading scientific expertise in yeast strains for industrial applications and a proven track record in bioethanol. All regulatory approvals have been obtained, and the transaction has closed.

The acquisition builds on Novonesis’ investment in MicroBioGen in 2013 and its existing 23% ownership stake, further strengthening a collaboration that has spanned more than a decade.

“With this acquisition, we strengthen our yeast and R&D expertise and take another step toward delivering on our 2030 strategy. We are pleased to welcome our new colleagues to Novonesis and bring these capabilities into our company, where we can unlock its broader potential. The acquisition reflects our disciplined approach to investing for growth,” says Ester Baiget, CEO of Novonesis.

As a pure-play biology company, Novonesis draws on deep expertise in microbiology and industrial fermentation. MicroBioGen’s advanced yeast-breeding capabilities complement this scientific foundation, creating opportunities to develop new biosolutions for customers across multiple industries.

“MicroBioGen has been a highly valued partner for more than a decade, and today marks the next step in that journey. By bringing together our complementary expertise and technologies, we can further strengthen our yeast capabilities and continue developing the biosolutions our customers need. We see potential for applications not only in bioethanol but also across other industries we serve, as is the case with many of our technologies,” says Claus Crone Fuglsang, Chief Scientific Officer at Novonesis.

Novonesis will continue to support MicroBioGen’s existing partners and ensure continuity in its collaborations.

Get in touch

Media relations

Benjamin Hjorth
Senior Press Manager
media-relations@novonesis.com+45 30 77 13 12

YY Circle Malaysia-branded robot brings the Company’s human-and-robot workforce approach into a hotel operating environment

SINGAPORE, Oct. 01, 2026 (GLOBE NEWSWIRE) — YYFORCE Inc. (NASDAQ: YFOR) (“YYFORCE” or the “Company”), a technology-enabled provider of workforce solutions and integrated facility management services, today announced the deployment of a YY Circle Malaysia-branded hospitality service robot at Aloft by Marriott Langkawi Pantai Tengah in Langkawi, Malaysia.

The deployment represents a practical application of YYForce’s strategy to bring service robotics into hospitality environments, supporting hotel teams with technology designed to assist with routine operational tasks.

The hotel recently featured the robot on its social media account, introducing it as a new addition to its team and providing a visible example of service robotics being introduced into a guest-facing hospitality setting. A video of the robot’s introduction is available on Aloft Langkawi Pantai Tengah’s official LinkedIn page.

Supporting Hotel Teams Through Service Robotics

YYForce’s approach combines human service capabilities with robotic assistance. By introducing robots into suitable workflows, the Company aims to help hospitality operators allocate employees’ time more effectively while maintaining personal interaction with guests.

The Langkawi deployment provides an opportunity to assess how service robotics can fit into daily hotel operations. Relevant evaluation areas include task completion, reliability, staff adoption and guest feedback. These observations can help inform future deployment decisions and service improvements.

“Hospitality is built around people, and we see robotics as a practical way to support the teams who deliver that experience,” said Mike Fu, Chief Executive Officer of YYForce. “Our focus is on bringing robots into real operating environments, understanding where they can add value, and developing solutions that work alongside employees. This deployment in Langkawi is a tangible step in that direction.”

Advancing YYForce’s Human-and-Robot Workforce Strategy

YYForce is pursuing opportunities to integrate workforce services and robotics across hospitality and facility operations. Its approach focuses on identifying suitable tasks, introducing appropriate technology and evaluating operational results before expanding deployment.

The Company believes experience gained in hotel environments can help strengthen its understanding of customer requirements, implementation needs and ongoing service support.

About YYFORCE

YYForce Inc. (Nasdaq: YFOR) is an AI-enabled workforce management and integrated facility management provider headquartered in Singapore and operating across Asia and beyond. Through its workforce technology and IFM businesses, YYForce provides workforce deployment, management and facility services solutions across multiple service industries.

The Company’s workforce platform, YY Circle, supports workforce deployment and management across sectors including hospitality, food and beverage, retail and other service industries. Within its IFM operations, YYForce combines frontline facility services with technology solutions designed to improve workforce productivity and operational efficiency.

YYForce’s long-term strategy is centered on building an integrated future workforce ecosystem in which human workers, intelligent software, automation and robotics increasingly work together to deliver services more efficiently.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company bases these forward-looking statements on its expectations and projections about future events, which the Company derives from the information currently available to it. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. Forward-looking statements involve inherent risks and uncertainties, and the forward-looking events discussed in this press release may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about the Company and a number of factors. These factors include, but are not limited to, the Company’s goals and strategies; the Company’s future business development, financial condition and results of operations, including the introduction of new products and services, expected changes in the Company’s revenues, costs and expenditures, anticipated customer growth, and demand for and market acceptance of the Company’s products and services; and industry, market and regulatory conditions, including competition, government policies and regulations affecting the Company’s industry, and other factors that may affect the Company’s financial condition, liquidity and results of operations. For a more detailed discussion of risk factors, please refer to the Company’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s most recent annual report on Form 20-F, as amended.

Investor Relations Contacts

Jason Zhi Yong Phua
Chief Financial Officer
YYForce Inc.
enquiries@yyforce.ai

Piacente Financial Communications
yfor@thepiacentegroup.com

Alongside other industry leaders, Definitive Healthcare demonstrates commitment to the highest standard of health data safety

FRAMINGHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), a provider of healthcare data and analytics, today announced that it has joined the Network Advertising Initiative (NAI). Membership in the NAI underscores Definitive Healthcare’s commitment to responsible data stewardship and rigorous privacy standards for sensitive healthcare data. Definitive Healthcare now provides its advertising customers with added assurance of its commitment to compliance with federal and state data protection requirements.

“Privacy is paramount when it comes to health data. Joining the NAI reconfirms that Definitive Healthcare, above all else, works to protect this type of data every single day,” said Sally Slarke, Senior Vice President of Commercial and Digital at Definitive Healthcare. “The stakes are high for companies looking to connect the right healthcare services with the right audiences. Even unintentional missteps or small compliance gaps can expose organizations to fines or significant legal risk. Acceptance into the NAI reinforces what we at Definitive Healthcare have known for years: our commercial healthcare data privacy standards adhere to the highest in the industry.”

Federal regulations as well as some state privacy laws protect individuals by shielding identifiable healthcare data from uses outside of healthcare-specific activities. Digital advertisers must navigate these privacy laws while still reaching highly valued audiences, such as healthcare consumers and providers. Definitive Healthcare’s membership in the NAI helps ensure its customers, including providers, pharmaceutical companies, and healthcare advertising agencies, that the data they maintain is at the highest level of privacy throughout the industry.

“Companies managing commercial healthcare data face a complex and continually evolving patchwork of legal and regulatory challenges. Definitive Healthcare’s NAI membership reflects its dedication to responsibly handle this data while prioritizing privacy,” said David LeDuc, Vice President of Public Policy at the NAI. “We look forward to collaborating with Definitive Healthcare to help guide their policies and data governance as it relates to consumer data used for health-related advertising, continually seeking to balance the beneficial outcomes of digital health advertising, while minimizing privacy risks.”

“We’re thrilled to join the NAI, further reinforcing our commitment to responsible data stewardship,” said Don Lee, Head of Digital Sales at Definitive Healthcare. “I’m especially excited to bring this additional layer of reassurance to customers who rely on our consumer data and solutions like Digital Audiences to fulfill the critical mission of connecting the right care with the right people in a compliant and responsible way.”

As a member of the NAI, Definitive Healthcare will be able to join industry leaders in supporting healthcare data safety. Earlier this year, NAI unveiled a framework to help businesses easily identify what is or isn’t sensitive healthcare data.

About Definitive Healthcare:
Definitive Healthcare is a data and analytics company focused on the business side of healthcare. The healthcare market is complex — our data makes it clearer. We cut through the noise to deliver the insights you need to make smarter, faster, more strategic decisions. Because when you succeed, healthcare gets better for everyone.

About the NAI:
Founded in 2000, the NAI is the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. The NAI works closely with its members, leading advertisers and publishers, and other key stakeholders to promote policies and voluntary practices for responsible data-driven advertising across digital media. The NAI is a champion of strong industry self-regulation and co-regulation, whereby industry efforts can play a complementary role to maximize industry compliance and reduce the burden on enforcement. To learn more, visit thenai.org.

Media Contacts:

Bethany Swackhamer
Definitive Healthcare
bswackhamer@definitivehc.com 

Jeff Rusack
Sōvyn
DefinitiveHC@sovyn.com 

Stockholm, October 1st, 2026 – Virtune today announces the completion of the quarterly rebalancing for the Virtune Stablecoin Index ETP (SE0026821282), listed on Nasdaq Stockholm, Nasdaq Helsinki and Xetra.

In addition to the Virtune Stablecoin Index ETP, Virtune’s product portfolio includes:

Virtune Arbitrum ETP
Virtune Avalanche ETP
Virtune Bitcoin ETP
Virtune Bitcoin Prime ETP
Virtune Bittensor ETP
Virtune BNB ETP
Virtune Chainlink ETP
Virtune Coinbase 50 Index ETP
Virtune Crypto Altcoin Index ETP
Virtune Crypto Top 10 Index ETP EUR
Virtune Crypto Top 10 Index ETP SEK
Virtune Hyperliquid ETP
Virtune Litecoin ETP
Virtune Polygon ETP
Virtune Staked Cardano ETP
Virtune Staked Ethereum ETP
Virtune Staked NEAR ETP
Virtune Staked Polkadot ETP
Virtune Staked Solana ETP
Virtune Stellar ETP
Virtune Sui ETP
Virtune XRP ETP

Index allocation as of September 30th (before rebalancing):

Ethereum: 29.62%
BNB: 15.06%
XRP: 14.87%
Solana: 13.93%
TRON: 7.45%
Chainlink: 5.94%
Stellar: 3.78%
Ethena: 3.38%
Aave: 3.26%
Canton: 2.72%

Index allocation as of September 30th (after rebalancing):

Ethereum: 28.88%
BNB: 16.28%
XRP: 15.31%
Solana: 13.18%
TRON: 9.05%
Chainlink: 4.93%
Stellar: 4.27%
Canton: 3.38%
Ethena: 2.37%
Aave: 2.37%

In connection with this quarter’s rebalancing, there are no changes to the crypto assets included in the index.

The index is rebalanced quarterly to reflect market changes and ensure it continues to represent the most relevant and qualitative crypto assets. The rebalancing adjusts weighting based on the square root of each crypto asset’s market capitalization and may involve removing or adding certain assets.

The performance of Virtune Stablecoin Index ETP in September was +13.53%.

Virtune Stablecoin Index ETP is a physically backed Exchange Traded Product (ETP) designed to offer investors a simple, secure, and cost-effective way to gain exposure to the expanding stablecoin ecosystem. The product tracks a diversified index of digital assets that provide the infrastructure and rails making stablecoins possible and that stand to benefit from their growing adoption and use.

If you, as an (institutional) investor, are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs, please do not hesitate to contact us at hello@virtune.com. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters, which cover updates on Virtune’s upcoming ETP launches and other news related to digital assets.

Press contact
Christopher Kock, CEO Virtune AB (Publ)
Christopher@virtune.com
+46 70 073 45 64

Virtune, headquartered in Stockholm, is a regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges. With regulatory compliance, strategic collaborations with industry leaders and our proficient team, we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

Owned land with a pathway to grid and behind-the-meter natural gas power expands FingerMotion’s Alberta AI infrastructure footprint

WEST PALM BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — FingerMotion, Inc. (Nasdaq: FNGR) (“FingerMotion” or the “Company”) today announced that it has entered into a binding Agreement of Purchase and Sale, together with BlueFlare Group Holdings Inc. (“BlueFlare”), to acquire approximately 20.2 acres of land at 409 Pioneer Trail S. in the Town of Hanna, Alberta. The site will be developed as Hanna Campus #1, an AI inference compute campus powered by a combination of local grid supply and behind-the-meter natural gas generation.

The agreement was fully executed on September 30, 2026. Hanna Campus #1 is in addition to the 99 MW Alberta development program the Company announced on September 10, 2026.

Transaction Highlights

• Binding agreement: executed September 30, 2026 by the seller, BlueFlare and FingerMotion, with FingerMotion and BlueFlare as covenantors.
• Site: approximately 20.2 acres (8.18 hectares) within the Town of Hanna, in east-central Alberta.
• Dedicated project company: title will be held by Hanna Campus #1 Inc., a single-purpose Alberta corporation, consistent with the one-site, one-project-company structure used across the Alberta program.
• Conditions and timing: a 60-day due diligence period covering title, environmental condition, zoning and permits for industrial, energy and data infrastructure use, utilities and access, and financing. Closing is scheduled 30 days after conditions are waived.

Planned Development

Hanna Campus #1 is planned for AI inference compute. The design contemplates [3] MW of local grid supply and [3] MW of behind-the-meter natural gas generation, for a contemplated capacity of [6] MW.

BlueFlare will design, build and operate the site’s power and infrastructure. Development permit applications are planned during the due diligence period, with construction to follow closing and permit approval.

Why Hanna

Access to power, not construction, is the binding constraint on new AI capacity. Hanna Campus #1 combines owned land, nearby grid infrastructure and the ability to add on-site generation, giving the Company a shorter path to energized capacity than a grid-only site.

Owning the land outright gives the Company long-term control of the site and its expansion. The Company intends to continue securing sites across Alberta as client demand for powered capacity requires.

Built to Fit the Community

Hanna Campus #1 is a small-scale site, not a hyperscale data center. Its contemplated capacity of [6] MW is a fraction of the hundreds of megawatts common at hyperscale campuses, and the facility is planned as a low-profile, warehouse-style building on an existing 20-acre parcel within the town.

The aim is for the campus to fit into Hanna, not stand out. BlueFlare hires locally first, will work with the Town through the municipal development permit process, and will staff the site around the clock as a responsible neighbor.

Management Commentary

“Speed to power is what separates AI infrastructure platforms today, and Hanna Campus #1 moves us from pipeline to property,” said Jolie Kahn, Chief Executive Officer of FingerMotion. “We are securing land we control, with grid access on the doorstep and a partner that builds and runs its own generation. This site sits alongside our 99 MW Alberta program and strengthens our position as a developer of powered capacity for AI workloads.”

“BlueFlare was built on three values: People, Communities and Innovation, and in that order. Alberta’s communities raised many of the people on our team, and Hanna is one of the places that has given this province so much to be proud of. This campus is our first step in giving back,” said Landon Ruszkowski, Chief Executive Officer of BlueFlare. “We hire locally first, we build to fit the community rather than stand out in it, and we measure success by what stays in Hanna long after construction ends. Working alongside the Town of Hanna, we intend to help build Alberta back, stronger than before.”

About FingerMotion, Inc.

FingerMotion, Inc. (Nasdaq: FNGR) is a technology company that, in addition to its historical mobile data and telecommunications platforms, is developing a North American behind-the-meter power and compute program in Alberta. Additional information is available at www.fingermotion.com.

About BlueFlare Group Holdings Inc.

BlueFlare Group Holdings Inc. is an oil and gas optimization, behind-the-meter power generation and EPC business specializing in the construction of modular data halls for AI and high-performance computing. BlueFlare self-performs design, procurement, construction and commissioning on its programs, and operates each site as its own microgrid with staff on site around the clock. BlueFlare is headquartered at Suite 700, 444 – 7th Avenue SW, Calgary, Alberta. For more information, contact sales@goblueflare.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the completion of the acquisition, satisfaction of closing conditions, planned power capacity, permitting, construction timing, and future site acquisitions. Words such as “plans,” “intends,” “expects,” “will” and similar expressions identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties, including the outcome of due diligence, the availability of financing, utility interconnection and permitting approvals, equipment availability, market demand for AI compute, and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. Actual results may differ materially. The Company undertakes no obligation to update these statements except as required by law.

Investor contact
FingerMotion, Inc.
Investor Relations
Email: ir@fingermotion.com
Website: www.fingermotion.com